Clinical Trial Update: Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) [Phase 4]

View source ↗

Summary

Phase 4 trial assessing immunogenicity and safety of a third FSME-IMMUN booster in adults previously vaccinated according to a rapid immunization schedule; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME-IMMUN 0.5 mL

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-borne | Phase 4 | Status: COMPLETED